15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 10 firms covering Allogene Therapeutics Inc, 7 rate it Buy or better, 3 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. The target range is very wide, $3.85 to $14.00 (about 3.6x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $8.19 sits 341% above the current $1.85. The rating mix has stayed broadly stable, with Buy-side ratings easing from 8 to 7 over recent months. On the fundamentals, the Street sees revenue growth near 0% this year and 80215% next, consensus EPS building from about $-0.14 next quarter toward $-0.65 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS10 ratings
Moderate Buy
Strong Buy00%
Buy770%
Hold330%
Sell00%
Strong Sell00%
Based on 10 analysts giving stock ratings to Allogene Therapeutics Inc.
As of Sep, 7 of 10 firms rate ALLO a Buy (3 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
ALLO EPS & revenue forecast
EPS · NEXT QUARTER
$-0.14
Range $-0.19 – $-0.07 · 7 analysts · -16% YoY
Next period, 7 analysts expect Allogene Therapeutics Inc to earn $-0.14 a share (range $-0.19 – $-0.07), versus $-0.17 a year earlier. Full-year consensus is $-0.59, growing to $-0.65 the year after.
REVENUE · NEXT QUARTER
$2.0K
Range $0 – $20.0K · 7 analysts · +0% YoY
Revenue is expected to reach $2.0K (range $0 – $20.0K), +0.0% year-over-year. Full-year consensus is $3.4M, rising to $12.1M next year.
Top analysts covering Allogene Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ALLO.
#1
Luca Issi
RBC Capital · Rank #1
Buy
$9.00+385.2% to target
Overall win rate
55%
+ Follow
#2
Roger Song
Jefferies · Rank #101
Buy
$10.00+439.1% to target
Overall win rate
43%
+ Follow
#3
RB
Robert Burns
HC Wainwright & Co. · Rank #199
Buy
$11.00+493.0% to target
Overall win rate
41%
+ Follow
#4
Reni J. Benjamin
JMP Securities · Rank #366
Buy
$8.00+331.3% to target
Overall win rate
32%
+ Follow
#5
John Newman
Canaccord Genuity · Rank #409
Buy
$14.00+654.7% to target
Overall win rate
30%
+ Follow
ALLO stock forecast FAQ
What is ALLO's average 12-month price target?+
The 9 analysts with a live target average $8.19 for Allogene Therapeutics Inc over the next 12 months, ranging from a $14.00 high to a $3.85 low.
Is ALLO stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 10 analyst ratings, 7 are Buy or Strong Buy, 3 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for ALLO?+
The Street-high target is $14.00 (Canaccord Genuity), and the Street-low is $3.85 (Bernstein). The average of all 9 active targets is $8.19.
How many Wall Street analysts cover ALLO?+
10 analysts have an active rating on Allogene Therapeutics Inc, and 9 firms carry a live 12-month price target.
Who is the most accurate analyst covering ALLO?+
Among analysts who currently cover ALLO, Luca Issi of RBC Capital has the strongest overall Quantellect track record (Rank #1). Their current call is Buy with a $9.00 target.
What is Allogene Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.14 per share (range $-0.19 – $-0.07) across 7 analysts. Full-year EPS is projected at $-0.59, rising to $-0.65 the following year.
How much revenue is Allogene Therapeutics Inc expected to report next quarter?+
Consensus revenue is $2.0K (range $0 – $20.0K). Full-year revenue is projected at $3.4M, growing to $12.1M next year.
Have analysts been upgrading or downgrading ALLO lately?+
As of Sep, 7 of 10 firms rate ALLO a Buy (3 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ALLO calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
